Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct;60(4):1367-1376.
doi: 10.1002/jmri.29267. Epub 2024 Jan 31.

Diffusion Tensor Imaging for Characterizing Changes in Triple-Negative Breast Cancer During Neoadjuvant Systemic Therapy

Benjamin C Musall  1 , David E Rauch  1 , Rania M M Mohamed  2 , Bikash Panthi  1 , Medine Boge  2 , Rosalind P Candelaria  2 , Huiqin Chen  3 , Mary S Guirguis  2 , Kelly K Hunt  4 , Lei Huo  5 , Ken-Pin Hwang  1 , Anil Korkut  2 , Jennifer K Litton  6 , Tanya W Moseley  2   4 , Sanaz Pashapoor  2 , Miral M Patel  2 , Brandy J Reed  1 , Marion E Scoggins  2 , Jong Bum Son  1 , Debu Tripathy  6 , Vicente Valero  6 , Peng Wei  3 , Jason B White  6 , Gary J Whitman  2 , Zhan Xu  1 , Wei T Yang  2 , Clinton Yam  6 , Beatriz E Adrada  2 , Jingfei Ma  1
Affiliations

Diffusion Tensor Imaging for Characterizing Changes in Triple-Negative Breast Cancer During Neoadjuvant Systemic Therapy

Benjamin C Musall et al. J Magn Reson Imaging. 2024 Oct.

Abstract

Background: Assessment of treatment response in triple-negative breast cancer (TNBC) may guide individualized care for improved patient outcomes. Diffusion tensor imaging (DTI) measures tissue anisotropy and could be useful for characterizing changes in the tumors and adjacent fibroglandular tissue (FGT) of TNBC patients undergoing neoadjuvant systemic treatment (NAST).

Purpose: To evaluate the potential of DTI parameters for prediction of treatment response in TNBC patients undergoing NAST.

Study type: Prospective.

Population: Eighty-six women (average age: 51 ± 11 years) with biopsy-proven clinical stage I-III TNBC who underwent NAST followed by definitive surgery. 47% of patients (40/86) had pathologic complete response (pCR).

Field strength/sequence: 3.0 T/reduced field of view single-shot echo-planar DTI sequence.

Assessment: Three MRI scans were acquired longitudinally (pre-treatment, after 2 cycles of NAST, and after 4 cycles of NAST). Eleven histogram features were extracted from DTI parameter maps of tumors, a peritumoral region (PTR), and FGT in the ipsilateral breast. DTI parameters included apparent diffusion coefficients and relative diffusion anisotropies. pCR status was determined at surgery.

Statistical tests: Longitudinal changes of DTI features were tested for discrimination of pCR using Mann-Whitney U test and area under the receiver operating characteristic curve (AUC). A P value <0.05 was considered statistically significant.

Results: 47% of patients (40/86) had pCR. DTI parameters assessed after 2 and 4 cycles of NAST were significantly different between pCR and non-pCR patients when compared between tumors, PTRs, and FGTs. The median surface/average anisotropy of the PTR, measured after 2 and 4 cycles of NAST, increased in pCR patients and decreased in non-pCR patients (AUC: 0.78; 0.027 ± 0.043 vs. -0.017 ± 0.042 mm2/s).

Data conclusion: Quantitative DTI features from breast tumors and the peritumoral tissue may be useful for predicting the response to NAST in TNBC.

Evidence level: 1 TECHNICAL EFFICACY: Stage 4.

Keywords: breast MRI; diffusion tensor imaging; peritumoral region; treatment response; triple‐negative breast cancer.

PubMed Disclaimer

References

    1. Moss JL, Tatalovich Z, Zhu L, Morgan C, Cronin KA. Triple-negative breast cancer incidence in the United States: ecological correlations with area-level sociodemographics, healthcare, and health behaviors. Breast Cancer 2021;28(1):82–91. - PMC - PubMed
    1. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer 2007;109(9):1721–1728. - PubMed
    1. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26(8):1275–1281. - PubMed
    1. Partridge SC, Gibbs JE, Lu Y, et al. MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival. AJR Am J Roentgenol 2005;184(6):1774–1781. - PubMed
    1. Hylton NM, Gatsonis CA, Rosen MA, et al. Neoadjuvant chemotherapy for breast cancer: functional tumor volume by MR imaging predicts recurrence-free survival-results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL. Radiology 2016;279(1):44–55. - PMC - PubMed

LinkOut - more resources